Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00734630 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

A Phase 4 study, sponsored by Forest Laboratories.

Completed
Registry status
Phase 4
Development phase
491
Enrollment target

NCT00734630 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 491 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00734630, a Phase 4 study, has completed, sponsored by Forest Laboratories.

COMPLETED
Registry status
Phase 4
Development phase
491 participants
Enrollment target

Study Summary

This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.

Interventions

  • DRUG Placebo
  • DRUG nebivolol

Trial Details

FieldValue
Enrollment Target 491 participants
Start Date 2008-08
Est. Completion 2010-05
Phase Phase 4

Sponsor

Forest Laboratories

145 total trials

What the Registry Record Tells You About NCT00734630

The ClinicalTrials.gov registry entry for NCT00734630 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00734630 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00734630 about?

NCT00734630 is a clinical study titled "Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients". This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.

What is the current status of trial NCT00734630?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 491 participants. The study started on 2008-08. Estimated completion is 2010-05.

What interventions are being tested in trial NCT00734630?

The interventions under investigation include: Placebo (DRUG), nebivolol (DRUG).

Who is sponsoring clinical trial NCT00734630?

This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.